ClinicalTrials.gg
CompletedNCT00480649Updated Nov 12, 2012

Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)

A Phase 4 interventional study of Salmeterol/ fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Completed at 14 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-12.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
424
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 46 studies testing Salmeterol Xinafoate in Asthma — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Asthma.

Enrollment
12th of 46
424 · median 128
Started
2004
with 6 others
Phase 4
26 of 46
none open now
Registered
23rd of 46
by date
Lead sponsor
22 of 46
GlaxoSmithKline

Among the 46 studies testing Salmeterol Xinafoate in Asthma, this one is the 12th largest by enrollment, is one of 7 that started in 2004, is one of 26 in phase 4, and was the 23rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 46 studies testing Salmeterol Xinafoate in Asthma is open now. The open studies under Asthma, anywhere →

About Salmeterol Xinafoate

Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies testing Salmeterol Xinafoate in Asthma as a file.
02

Study summary

The primary study objective is to demonstrate the clinical effectiveness of SERETIDE therapy compared to the current care in management of moderate to severe persistent asthma patients in Korea.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • SERETIDE
  • asthma
  • Korean
  • ACT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18 years and over who are willing to give a written consent to participate in the study.
  • Subjects with a documented clinical history of reversible airways obstruction (history taking is acceptable) for at least 12 months and, in the opinion of the investigator, is able to comply with therapy and to complete the Daily Record Cards (DRCs) correctly.
  • Subjects able to demonstrate the ability to effectively (physically and/or mentally) use a DISKUS (a dummy DISKUS provided for test).
  • A female is eligible to enter and participate in this study
  • Subjects with access to telephone (mobile or landline at home)

Exclusion criteria

Exclusion criteria:

  • Previous use of ICS /LABA combination inhaler (SYMBICORT (Astrazeneca) or SERETIDE) 12 weeks prior to Visit 1.
  • Subjects with known or suspected to inhaled or Beta2-agonists.
  • Subjects who have had other changes in their regular asthma medication within 2 weeks of Visit 1.
  • Subjects who have had a lower respiratory tract infection within 4 weeks of Visit 1.
  • Subjects who have a smoking history of 10 pack years (e.g. 10 cigarettes/day for 20 years or 20 cigarettes/day for 10 years or 40 cigarettes/day for 5 years) or more at the time of Visit 1 (Current smoker can be included even if his/her smoking history is less than 10 pack years at the time of Visit 1).
  • Subjects who suffer from serious, uncontrolled diseases (including serious psychological disorders) likely to interfere with the study.
  • Subjects who are on immunotherapy
  • Subjects who have taken any drugs within 4 weeks of Visit 1.
  • Subjects who have, in the opinion of the investigator, evidence of alcohol or drug abuse.
  • Females who are pregnant, lactating or are of child bearing potential and are likely to become pregnant. Females of childbearing age may be included if, in the opinion of the investigator, they are exerting adequate precautions.
  • Subjects who have previously been enrolled into this study
  • Patients on regular oral or parenteral steroid therapy in the last 4 weeks or more than 3 courses of steroid in the last 6 months
  • Subjects who have or PEFR of less than 50% predictive value.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
424 participants (actual)

Study arms

  • Active comparator
    Sal/FP 50/250mcg

    SERETIDE 50/250

    Drug: Salmeterol/ fluticasone propionate

  • Active comparator
    Sal/FP 50/500mcg

    SERETIDE 50/500

    Drug: Salmeterol/ fluticasone propionate

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint for this trial is mean morning PEFR LOCF at 52 weeks as collected in diary cards over the last 2 weeks preceding the 52 weeks visit.

    Time frame: 52 weeks after randomization

Secondary outcomes

  1. Secondary measures of efficacy consist of clinical efficacy and health outcome measurements.

    Time frame: 52 weeks after randomization

07

Study locations

14 sites
  • GSK Investigational Site
    Anyang-Si, 431-070, Korea, Republic of
  • GSK Investigational Site
    Busan-si, Korea, Republic of
  • GSK Investigational Site
    Busan, Korea, Republic of
  • GSK Investigational Site
    Junjoo-Si, Korea, Republic of
  • GSK Investigational Site
    Kyungki-Do Anyang-si, Korea, Republic of
  • GSK Investigational Site
    Kyungki-Do, Korea, Republic of
  • GSK Investigational Site
    Pusan, 602-739, Korea, Republic of
  • GSK Investigational Site
    Pusan, Korea, Republic of
  • GSK Investigational Site
    Seoul, 120-752, Korea, Republic of
  • GSK Investigational Site
    Seoul, 140-743, Korea, Republic of
  • GSK Investigational Site
    Seoul, 152-703, Korea, Republic of
  • GSK Investigational Site
    Seoul, Korea, Republic of
  • GSK Investigational Site
    서울시, Korea, Republic of
  • GSK Investigational Site
    전주시, Korea, Republic of
08

References and documents

Publications

  • Jung KS, Uh ST, Lee YC, Shim JJ, Park SK, Williams AE, Chan R. Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. Curr Med Res Opin. 2008 Dec;24(12):3571-82. doi: 10.1185/03007990802588737. PubMed 19032138 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2007
First posted
May 31, 2007
Start
Jan 2004
Primary completionActual
Sep 2005
CompletionActual
Sep 2005
Last update
Nov 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00480649
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 31, 2007
Start date
Jan 2004
Primary completion
Sep 2005
Completion
Sep 2005
Last update
Nov 12, 2012

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone

Start the discussion